GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remedent Inc (OTCPK:REMI) » Definitions » Scaled Net Operating Assets

Remedent (Remedent) Scaled Net Operating Assets : 0.61 (As of Dec. 2020)


View and export this data going back to 2000. Start your Free Trial

What is Remedent Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Remedent's operating assets for the quarter that ended in Dec. 2020 was $7.48 Mil. Remedent's operating liabilities for the quarter that ended in Dec. 2020 was $2.91 Mil. Remedent's Total Assets for the quarter that ended in Sep. 2020 was $7.48 Mil. Therefore, Remedent's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2020 was 0.61.


Remedent Scaled Net Operating Assets Historical Data

The historical data trend for Remedent's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remedent Scaled Net Operating Assets Chart

Remedent Annual Data
Trend Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.53 0.68 0.99 0.57

Remedent Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.58 0.60 0.60 0.61

Competitive Comparison of Remedent's Scaled Net Operating Assets

For the Medical Instruments & Supplies subindustry, Remedent's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Remedent's Scaled Net Operating Assets Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Remedent's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Remedent's Scaled Net Operating Assets falls into.



Remedent Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Remedent's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2020 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2020 )
=(Operating Assets (A: Mar. 2020 )-Operating Liabilities (A: Mar. 2020 ))/Total Assets (A: Mar. 2019 )
=(7.394-2.883)/7.896
=0.57

where

Operating Assets(A: Mar. 2020 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=7.509 - 0.115
=7.394

Operating Liabilities(A: Mar. 2020 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.888 - 0.005 - 0
=2.883

Remedent's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2020 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2020 )
=(Operating Assets (Q: Dec. 2020 )-Operating Liabilities (Q: Dec. 2020 ))/Total Assets (Q: Sep. 2020 )
=(7.48-2.913)/7.475
=0.61

where

Operating Assets(Q: Dec. 2020 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=7.563 - 0.083
=7.48

Operating Liabilities(Q: Dec. 2020 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.918 - 0.005 - 0
=2.913

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Remedent Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Remedent's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Remedent (Remedent) Business Description

Traded in Other Exchanges
N/A
Address
Zuiderlaan 1-3, Box 8, Ghent, BEL, 9000
Remedent Inc is a manufacturer of cosmetic dentistry products in Europe. The company is engaged in the research, development, and manufacturing of oral care and cosmetic dentistry products. It designs, develops, manufactures, and distributes cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, the Middle East, and the United States. The product line of the company includes SmileWise, the SmileMe mirror, and the Condor intra-oral 3D scanner.
Executives
Stuart Steinberg 10 percent owner 85 BELLEVUE AVENUE, RYE NY 10580
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Gruber & Mcbaine Capital Management Llc 10 percent owner 234 VAN NESS, STE 5, SAN FRANCISCO CA 94133
Stephen Farley Ross director, officer: CFO; Secretary XAVIER DE COCKLAAN 42 DEURLE C9 9831
Fred Kolsteeg director XAVIER DE COCKLAAN 42 DEURLE C9 9831
Acker Philippe Van director C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831
Robin List other: Former Officer and Director XAVIER DE COCKLAAN 42 DEURLE C9 9831
Roger Leddington officer: Sr VP & Head of US Marketing C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 DEURLE C9 9831
Guy Devreese director, officer: Chairman of the Board XAVIER DE COCKLAAN 42 DEURLE C9 9831
Judd Darrin Hoffman officer: VP Worldwide Sales/Operations 702A JUANITA AVENUE REDONDO BEACH CA 90277
Nv Lausha 10 percent owner C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831

Remedent (Remedent) Headlines

From GuruFocus

Making Money from Smiles

By Frank Lind Frank Lind 05-26-2011